POLD1 and neoplasm: The frequency of POLE/POLD1 mutations in GC patients was approximately 8% and the tumours were characterized by adaptive immune resistance tumour microenvironment (TME), deficient mismatch repair (dMMR) status but also by higher PD-L1 expression level, higher TMB, higher MSI and lower aneuploidy score [131].